Cerebain Biotech Corp. is looking for considering multiple strategic alternatives. "We are committed to evaluating strategic alternatives that enhance value for our shareholders while maintaining our focus on the continued development of our device for the treatment of Alzheimer's Disease as well as aggressively managing our operating expenses," said Eric Clemons, Chief Executives Officer.